Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc.

NNASDAQ:XLO
7.70
USD
-0.37
(-4.64%)
-0.80EPS
59.62MMarket Cap
Mar 03Next Earn

Total Valuation

USD

As of September 30, 2026, Xilio Therapeutics, Inc. carries a market capitalization of 59.62M, placing it among publicly traded companies globally. Its enterprise value stands at -56.60M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap59.62M
Enterprise Value-56.60M

Important Dates

Xilio Therapeutics, Inc.'s next confirmed earnings release is scheduled for March 3, 2027.

Earnings Date3/3/2027

Share Statistics

As of September 30, 2026, Xilio Therapeutics, Inc. has 6.59M shares outstanding.

Shares Outstanding6.59M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 2.29, and the price-to-book ratio stands at 0.87.

PS Ratio2.29
PB Ratio0.87
P/TBV Ratio0.87
P/FCF Ratio-2.27
P/OCF Ratio-2.22

Financial Position

As of September 30, 2026, Xilio Therapeutics, Inc. maintains a current ratio of 4.72, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities.

Current Ratio4.72
Quick Ratio4.56
Debt / Equity8.73
Debt / EBITDA-0.15

Financial Efficiency

USD

These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -8.56, reflecting losses generated across the asset base. The company generates approximately 723,815.79 in revenue per employee across its workforce of 76.00, a quick read on workforce productivity versus industry peers.

Return on Assets (ROA)-8.56
Revenue Per Employee723,815.79
Employee Count76.00

Stock Price Statistics

USD

As of the close on November 16, 2026, Xilio Therapeutics, Inc.'s stock has declined approximately 22.23% over the past 52 weeks. The 50-day moving average sits at 8.67, while the 200-day moving average is 8.48.

52-Week Price Change-22.23%
50-Day Moving Average8.67
200-Day Moving Average8.48

Income Statement

USD

Over the twelve months ended September 30, 2026, Xilio Therapeutics, Inc. generated 55.01M in revenue and converted that into -11.49M in net income, yielding earnings per share of -0.80. EBITDA reached -39.87M, while operating income came in at -41.19M.

Revenue55.01M
Operating Income-41.19M
Pretax Income-11.49M
Net Income-11.49M
EBITDA-39.87M
EBIT-41.19M
Earnings Per Share (EPS)-0.80

Balance Sheet

USD

As of September 30, 2026, Xilio Therapeutics, Inc. holds 122.18M in cash and equivalents against 5.96M in total debt, resulting in a net debt position of -122.18M. Total book value stands at 68.23M, with working capital of 99.70M providing operational flexibility.

Cash & Cash Equivalents122.18M
Total Debt5.96M
Net Debt-122.18M
Equity (Book Value)68.23M
Book Value Per Share10.36
Working Capital99.70M

Cash Flow

USD

Xilio Therapeutics, Inc. produced -56.90M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -728,000.00 in capital expenditures, free cash flow totaled -57.62M - equivalent to -4.14 per share.

Operating Cash Flow-56.90M
Capital Expenditures-728,000.00
Free Cash Flow-57.62M
FCF Per Share-4.14

Margins

These figures cover the twelve months ended September 30, 2026. The operating margin of -74.87 and net profit margin of -20.89 provide insight into operational efficiency.

Operating Margin-74.87
Pretax Margin-20.89
Profit Margin-20.89
EBITDA Margin-72.48

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -44.14: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -127.59, meaning Xilio Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-127.59
FCF Yield-44.14

Stock Splits

Xilio Therapeutics, Inc.'s most recent stock split took place on March 16, 2026 with a 14:1 split ratio.

Last Split Date3/16/2026
Split Ratio14:1

Scores

As of September 30, 2026, Xilio Therapeutics, Inc. has an Altman Z-Score of -3.75, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-3.75